Divergent TIR signaling domains in TLR7 and TLR9 control opposing effects on systemic autoimmunity
Journal of Clinical Investigation · 03.11.2025 · 135 (21)
DOI: 10.1172/jci189566 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 12.08.2025. Verfasst von Claire Leibler und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA. Hauptthemen laut MEDLINE: Toll-Like Receptor 7, Toll-Like Receptor 9, Signal Transduction, Lupus Erythematosus, Systemic. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIH HHS, NIDDK NIH HHS.
Abstract (Originalsprache)
Toll like receptor (TLR) 7 and 9, endosomal sensors for RNA and DNA, are key mediators of autoreactivity. Although generally considered homologous, they paradoxically have opposing effects on lupus: TLR7 exacerbates the disease while TLR9 protects from it How they mediate opposing effects in autoimmunity remains undetermined. We hypothesized that differences in signaling qualities of the Toll-Interleukin 1 Receptor (TIR) domains of TLR7 and TLR9 could be responsible for their opposing effects. To test this, we introduced the TIR domain of TLR9 into the endogenous Tlr7 locus and the TLR7 TIR domain into the endogenous Tlr9 locus of mice, creating chimeric molecules termed TLR779 and TLR997. Lupus-prone MRL/lpr mice carrying Tlr 779 had greatly ameliorated disease, while MRL/lpr mice carrying Tlr 997 had markedly exacerbated disease compared with respective Tlr WT mice. These experiments establish that TLR7 and TLR9 TIR domains have divergent properties and control disease quality, thus explaining the longstanding “TLR paradox”.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
- Univ. Bordeaux, CNRS, ImmunoConcEpT, and.
- CHU de Bordeaux, Department of Immunology, UMR 5164, F-33000 Bordeaux, France.
- Department of Laboratory Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.
- Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Förderung
- NIAID NIH HHS
- NIH HHS
- NIDDK NIH HHS
- National Institute of Allergy and Infectious Diseases
Zitieren
APA
Leibler, C., Thomas, K. B., Josensi, C., Levack, R. C., Smita, S., John, S., Wikenheiser, D. J., Bastacky, S., Gingras, S., Nickerson, K. M., & Shlomchik, M. J. (2025). Divergent TIR signaling domains in TLR7 and TLR9 control opposing effects on systemic autoimmunity. Journal of Clinical Investigation, 135(21). https://doi.org/10.1172/jci189566
Vancouver
Leibler C, Thomas KB, Josensi C, Levack RC, Smita S, John S, et al. Divergent TIR signaling domains in TLR7 and TLR9 control opposing effects on systemic autoimmunity. Journal of Clinical Investigation. 2025;135(21). doi:10.1172/jci189566
BibTeX
@article{Leibler2025,
author = {Leibler, Claire and Thomas, Kayla B and Josensi, Coralie and Levack, Russell C and Smita, Shuchi and John, Shinu and Wikenheiser, Daniel J and Bastacky, Sheldon and Gingras, Sebastien and Nickerson, Kevin M and Shlomchik, Mark J},
title = {Divergent TIR signaling domains in TLR7 and TLR9 control opposing effects on systemic autoimmunity},
journal = {Journal of Clinical Investigation},
year = {2025},
volume = {135},
number = {21},
doi = {10.1172/jci189566}
}
EUVIMED